Early viral kinetics during treatment of chronic hepatitis C virus infection with pegylated interferon alpha plus ribavirin in Taiwan

被引:14
作者
Hsu, Ching-Sheng
Liu, Chun-Jen
Lai, Ming-Yang
Chen, Pei-Jer
Kao, Jia-Horng
Chen, Ding-Shinn
机构
[1] Natl Taiwan Univ Hosp, Hepatitis Res Ctr, Taipei 100, Taiwan
[2] Buddhist Tzu Chi Gen Hosp, Dept Hepatogastroenterol, Dept Internal Med, Taipei Branch, Taipei, Taiwan
[3] Natl Taiwan Univ, Coll Med, Dept Internal Med, Taipei 10764, Taiwan
[4] Natl Taiwan Univ, Coll Med, Dept Med Res, Taipei 10764, Taiwan
[5] Natl Taiwan Univ, Coll Med, Hepatitis Res Ctr, Taipei 10764, Taiwan
[6] Natl Taiwan Univ, Coll Med, Grad Inst Clin Med, Taipei 10764, Taiwan
关键词
hepatitis C virus; viral kinetics; pegylated interferon; interferon; ribavirin;
D O I
10.1159/000105444
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Objectives: Early hepatitis C viral ( HCV) kinetics following pegylated interferon-alpha (PEG-IFN) and ribavirin help to assess treatment in the Western world. Whether this functions in Taiwanese patients remains unknown. Studying the early HCV kinetics in Taiwanese patients may clarify this issue. Methods: Six chronic hepatitis C patients were enrolled. A PEG-IFN-alpha dose was administered at week 1, then it was administered weekly with daily ribavirin for 24 weeks. Serum HCV RNA levels were determined frequently during the trial and qualitatively at week 49. Kinetic parameters epsilon ( effectiveness at inhibiting viral production) and delta ( loss rate of infected cells) were estimated from viral loads and alanine aminotransferase ( ALT) kinetics, respectively. Results: All serum HCV RNA levels became undetectable at week 12. The epsilon ranged from 0.4128 to 0.9904 and delta from 0.0019 to 0.1245. The log values of viral load differences between day 7 and 14 ranged from 0.15 to 1.21. Only 1 patient had an abnormal ALT level at week 49. Conclusions: Viral kinetic parameters in Taiwanese patients were similar to those in Western studies. However, the early viral decline pattern and viral negativity rate in Taiwanese patients might be different from Caucasian patients. Further large-scale studies to clarify this issue are ongoing. Copyright (C) 2007 S. Karger AG, Basel.
引用
收藏
页码:310 / 315
页数:6
相关论文
共 30 条
[2]   An algorithm for the grading of activity in chronic hepatitis C [J].
Bedossa, P ;
Poynard, T .
HEPATOLOGY, 1996, 24 (02) :289-293
[3]   Viral kinetics in genotype 1 chronic hepatitis C patients during therapy with 2 different doses of peginterferon alfa-2b plus ribavirin [J].
Buti, M ;
Sanchez-Avila, F ;
Lurie, Y ;
Stalgis, C ;
Valdés, A ;
Martell, M ;
Esteban, R .
HEPATOLOGY, 2002, 35 (04) :930-936
[4]  
Chen D S, 1995, Princess Takamatsu Symp, V25, P27
[5]   HEPATITIS-C VIRUS-INFECTION IN AN AREA HYPERENDEMIC FOR HEPATITIS-B AND CHRONIC LIVER-DISEASE - THE TAIWAN EXPERIENCE [J].
CHEN, DS ;
KUO, GC ;
SUNG, JL ;
LAI, MY ;
SHEU, JC ;
CHEN, PJ ;
YANG, PM ;
HSU, HM ;
CHANG, MH ;
CHEN, CJ ;
HAHN, LC ;
CHOO, QL ;
WANG, TH ;
HOUGHTON, M .
JOURNAL OF INFECTIOUS DISEASES, 1990, 162 (04) :817-822
[6]  
Colombatto P, 2003, ANTIVIR THER, V8, P519
[7]   Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. [J].
Fried, MW ;
Shiffman, ML ;
Reddy, KR ;
Smith, C ;
Marinos, G ;
Goncales, FL ;
Haussinger, D ;
Diago, M ;
Carosi, G ;
Dhumeaux, D ;
Craxi, A ;
Lin, A ;
Hoffman, J ;
Yu, J .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (13) :975-982
[8]   Side effects of therapy of hepatitis C and their management [J].
Fried, MW .
HEPATOLOGY, 2002, 36 (05) :S237-S244
[9]   Early hepatitis C virus changes and sustained response in patients with chronic hepatitis C treated with peginterferon α-2b and ribavirin [J].
Gallegos-Orozco, JF ;
Loaeza-del Castillo, A ;
Fuentes, AP ;
García-Sandoval, M ;
Soto, L ;
Rodríguez, R ;
Gutiérrez-Ruíz, MC ;
Gutiérrez-Reyes, G ;
Bonder, A ;
Olivera, MA ;
Kershenobich, D .
LIVER INTERNATIONAL, 2005, 25 (01) :91-95
[10]   Differences in treatment outcome for hepatitis C among ethnic groups [J].
Hepburn, MJ ;
Hepburn, LM ;
Cantu, NS ;
Lapeer, MG ;
Lawitz, EJ .
AMERICAN JOURNAL OF MEDICINE, 2004, 117 (03) :163-168